Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (2274)	2/22/2008 11:38:51 AM
From: Jibacoa	Read Replies (1) \| Respond to of 3722

ORXE, the old GLGC, seems to have found support at the $0.63 level.<g> bigcharts.marketwatch.com It released today its 4thQ results.Revenue was $0.7M vs. $7.2M in Dec 2006 but a licensing agreement with H. Lundbeck that was signed in June 2007 & from which payments were received in 2007 is being recognized over a one year service life,amount $3M.<g> R&D expenses, when compared to the 4thQ of 2006, increased $0.3M. ORXE has sold its Genomics Assets to Ocimum Biosolutions for $7M & sold its Gene Logic Laboratories for $15M The revenues had increased at double digits on the 2nd & 3rd Qs & it was able to trim some its losses. In the 4thQ ORXE established 4 drug repositioning & development partnerships with Abbott Laboratories, H. Lundbeck, Merck-Serono, and Solvay.It says that in vivo testing of its GL1001 shows potential efficacy for treatment of IBD & it started evaluating more than 27 drug candidates for "new therapeutic applications".<g> The stock is trading around 0.35xBV & the insiders hold > 20% The short ratio was up 40% & is > 16x its ADV The March 2000 H was $152.50 Seems worth of keeping on a WL.<g> bigcharts.marketwatch.com Bernard